Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer.
about
Advances in drug delivery system for platinum agents based combination therapyEfficient human breast cancer xenograft regression after a single treatment with a novel liposomal formulation of epirubicin prepared using the EDTA ion gradient methodLiposomal Formulations in Clinical Use: An Updated Review.Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinicLipoplatin formulation review article.Interaction of liposome-encapsulated cisplatin with biomolecules.Paclitaxel-loaded poly(glycolide-co-ε-caprolactone)-b-D-α-tocopheryl polyethylene glycol 2000 succinate nanoparticles for lung cancer therapy.Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer.Lipid-based nanoparticle delivery of Pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinomaEconomic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South KoreaTwo consecutive days of treatment with liposomal cisplatin in non-small cell lung cancerClinical developments of chemotherapeutic nanomedicines: polymers and liposomes for delivery of camptothecins and platinum (II) drugs.Liposomes, a promising strategy for clinical application of platinum derivatives.Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents.Nanoparticle formulations of cisplatin for cancer therapy.Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells.Recent advances in the preparation and application of multifunctional iron oxide and liposome-based nanosystems for multimodal diagnosis and therapy.In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin (lipoplatin™).A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-small Cell Lung Cancer.Lipoplatin treatment in lung and breast cancer.Nanomedicine applications in the treatment of breast cancer: current state of the art.Dual-Drug Containing Core-Shell Nanoparticles for Lung Cancer TherapyTherapeutic nanosystems for oncology nanomedicine.Thermosensitive liposomal cisplatin in combination with local hyperthermia results in tumor growth delay and changes in tumor microenvironment in xenograft models of lung carcinoma.Feasibility of haloperidol-anchored albumin nanoparticles loaded with doxorubicin as dry powder inhaler for pulmonary delivery
P2860
Q26771390-F4898FD1-A3FA-40D0-B2DC-87A1F3B08E47Q28540782-029675AA-EA6C-4205-9032-9095E9B5DE69Q33850427-5E5F7078-5BB0-492F-8CE2-1AA464089AFCQ33911056-A72C8778-BD8F-4D1A-A958-3EB992948148Q34214923-9BFA77AC-CE41-47C8-ABF2-3FCF11FE43EBQ34295156-B8F2BEBA-F86F-4B7F-8232-9AD178F11326Q34733497-CA318E03-500C-44FA-AAA9-423463F2E351Q35233464-49DFE604-B425-4BE8-858A-C6653EABB127Q36014101-CD44E2ED-1749-4679-B0CD-199451237DA0Q36092393-A5B30418-40B9-44A6-B75C-6E0AB9FEB852Q36403215-6C640DE5-DEF7-4380-91BE-085B65DB09E4Q38075544-29AF2DAC-F988-4F51-BE35-5F6D2EBEFACBQ38087423-5618302E-67EA-4911-BB6E-F6E2A2C15785Q38546964-E830AE0C-317F-4E2F-9930-38BE0F980DE4Q38723829-3E332224-D0C9-49F7-863C-F2BC8392EB8BQ39014487-FFBEB234-DCCC-4E81-97A9-4DD37F1FB3A4Q39030223-020F75E6-8720-4775-B923-427AA7936782Q39782222-E5F3F84A-00F7-492F-BA21-2878283937CBQ40040290-0B3B9A8E-9023-4D7F-B8DD-B659760EDF78Q40631888-DDDAF5E1-98C0-480F-92E1-6F3033F5BE42Q41483629-C0A5F081-A677-4881-937E-AB26A024DEE4Q42379033-1A5CB333-F950-463F-B730-6D2EEABA73D7Q48421332-31A34D31-9125-4FF2-BD15-48971BFBEF94Q51289380-67B687FC-D01A-43E1-AC6C-261B08C056DFQ57183019-8384F0CF-25DB-4F4A-9C52-7DD111124C54
P2860
Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Phase II study of liposomal ci ...... V) non-small cell lung cancer.
@en
Phase II study of liposomal cisplatin
@nl
type
label
Phase II study of liposomal ci ...... V) non-small cell lung cancer.
@en
Phase II study of liposomal cisplatin
@nl
prefLabel
Phase II study of liposomal ci ...... V) non-small cell lung cancer.
@en
Phase II study of liposomal cisplatin
@nl
P2093
P1433
P1476
Phase II study of liposomal ci ...... V) non-small cell lung cancer.
@en
P2093
A Athanasiou
C Karanikas
N Mylonakis
P304
P356
10.1016/J.LUNGCAN.2009.06.017
P577
2009-07-22T00:00:00Z